Despite professional medical society recommendations to offer carrier screening for over 100 different germline disorders to all individuals of reproductive age, insurance coverage for large panels continues to remain a barrier to widespread adoption. Moreover, not all laboratories have the operational means to implement such testing at the cost, turnaround time, and throughput typically required in the setting of prenatal care.

In this recorded webinar, Linda Hasadsri, director of the molecular technologies laboratory at Mayo Clinic, presents the pros and cons of utilizing a custom targeted genotyping array for carrier screening of over 200 different genetic disorders, their unique approach to supplemental coverage and confirms, and, finally, their discovery yield in the first 8,000 samples received for testing.